Pulmo BioTech Inc. Has Revealed That Its PulmoBind(TM) Pulmonary Vascular Diagnostic Product Candidate May Have Particular Applicability To Post Operative Patient Care And Diagnostics

NEW YORK, June 29, 2010 (GLOBE NEWSWIRE) -- "Pulmonary Embolism (PE) is a potentially fatal condition that occurs when a blood clot forms within the vascular system of the body, becoming detached and then lodged in the pulmonary circulatory system of the lungs. Lung tissue death occurs beyond the embolism and depending on the size of the embolism this can result in conditions ranging from shortness of breath to death. There are many different causes for PE, but one of the times that people are most vulnerable is after surgery. The nature of the surgery itself coupled with post-operative care and reduced mobility can potentially contribute to a patient experiencing PE. If the early experimental results of PulmoBind™ are confirmed by further experiments and clinical trials, then PulmoBind™, which is a simple non-invasive diagnostic test, could be of particular benefit to patients who have undergone surgical intervention." – Garry McCann, CEO, Pulmo BioTech Inc.

About Pulmo BioTech Inc.

Pulmo BioTech Inc. (OTCBB:PLMO) (Frankfurt:PB0) specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stockholders.

ISIN: US7458451074

CUSIP: 745845107

WKN: A0RDTZ

About PulmoScience Inc.

PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind™.

PulmoScience was conceived within the Montreal Heart Institute "MHI" (a world renowned hospital and educational facility). Jointly owned by MHI subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn Dupuis (the scientific director and originator of the PulmoBind™ Molecular Imaging technology), and by Pulmo BioTech Inc. as the funding partner, PulmoScience Inc. aims to develop this unique and exciting technology, to fund necessary trials, and to bring the products to market.